moderna goldman sachs

Moderna slips

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Hosted on MSN · 1d

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Seeking Alpha on MSN · 1d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

18hon MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

14hon MSN

Goldman Sachs upgrades RH on improved execution, demand trends

Goldman Sachs upgraded RH (NYSE:RH) to "Neutral" from "Sell" given improving demand trends, strategic supply chain shifts, and the company's expectation of turning free cash flow positive next year.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results